Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok4. fázis

Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking

A legfontosabb adatok

Ki végzi
Legacy Health System
Hol
Portland (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
4. fázis
Résztvevők
44 fő, tervezett
Kezdés
2026. febr. 10.
Várható befejezés
2027. szept. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Daridorexant 50 mg
  • Placebo
A regiszteradat frissítve
2026. január 9.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adult cigarette smokers who are willing to try to cut down or stop smoking for 3 weeks. It tests daridorexant, a sleep medicine, against a placebo (dummy pill).

Életkor
18-55 years
Nem
All sexes
A betegség stádiuma
Smoking more than 10 cigarettes a day, for 1 year or longer.
Korábbi kezelés
People cannot join if they currently use quit-smoking medicines or therapy (nicotine patch or gum, buproprion, varenicline, cognitive behavioral therapy for smoking). People cannot join if they currently take sleep medicines, ADHD stimulants or anti-seizure drugs.

A részvétel fő kizáró okai

  • Pregnant or breastfeeding
  • Sleep apnea, narcolepsy or another diagnosed sleep disorder
  • Substance use disorder other than nicotine, or a serious neurological or psychiatric disorder
  • Thyroid problems or COPD
  • BMI of 33 or higher

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Egyéb feltételek

  • INCLUSION
  • Adult participants who are cigarette smokers, 18-55 years of age
  • Smokers: greater than 10 cigarettes/day
  • Smoking for 1 year or longer
  • Willingness to try to reduce or stay abstinent from cigarettes, smoking cessation aides (including nicotine gum or patches), smokeless tobacco, or electronic cigarettes for 3 weeks during the study
  • Willingness to monitor sleep at home with an external device and maintain a simple sleep and smoking diary for 3 weeks
  • Willingness to take a 5-min, mobile-based test 3X/day for 3 days/week during the 3 weeks
  • Ability to travel to three Study Visits
  • Are willing to abstain from consuming grapefruit products during the study
  • Have an iPhone, best with iOS 17 or newer; EXCLUSION:
  • Are currently taking any pharmaceutical drugs for smoking cessation, including: Nicotine patch or nicotine gum, buproprion (Wellbutrin, Zyban), varenicline (Chantix, Champix), other behavioral interventions such as cognitive behavioral therapy for smoking
  • Are currently using cannabis or alcohol for sleep. Are currently taking any pharmaceutical drugs for insomnia, such as eszopiclone (Lunesta), zaleplon (Sonata) or zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) benzodiazepines, or opioids
  • Are currently taking stimulants commonly used for ADHD, such as methylphenidate (Ritalin Concerta, Daytrana) or amphetamines (Adderall, Dexedrine, Vyvanse)
  • Are currently taking anti-seizure drugs, including lamotrigine, pregabalin (Lyrica), or gabapentin (Neurontin, Horizant, or Gralise)
  • Have non-nicotine substance dependence (diagnosed with substance use disorder, including alcohol or cannabis use disorder (current cannabis use is acceptable, and past illicit drug use is acceptable if greater than 2 months prior to testing and does not meet current criteria for substance use disorders (SUDs) according to DSM-5)
  • Have a major neurological disorder such as Parkinson's disease, epilepsy, Alzheimer's disease, multiple sclerosis, or any other serious neurological disorder
  • Have a history of serious psychiatric disorders including bipolar disorder, schizophrenia, or suicidality
  • Had a stroke or head injury which caused loss of consciousness for longer than three minutes in the past 1 year
  • Are pregnant or breastfeeding
  • Have been diagnosed with sleep apnea or other diagnosed sleep disorders such as narcolepsy
  • Have been diagnosed with thyroid problems
  • Have been diagnosed with COPD
  • Have been doing variable shift work in the past 1 month or traveled more than 1 time zone in past month
  • Are currently taking the following medications, supplements, or food: Daridorexant can interact with strong inhibitors of CYP3A4, which should be discussed with The Study Doctor's office (some of these include clarithromycin, diltiazem, erythromycin, itraconzale, ketoconazole, ritonavir, and verapamil)
  • Have a BMI of 33 or higher

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 55 év között vagy?

Helyszínek itt: Egyesült Államok

  • Legacy Research InstitutePortland, Egyesült ÁllamokContact: Barbara A. Sorg, PhDToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

Tobacco use is the leading cause of preventable death in the U.S., with 480,000 deaths per year and 7.7 million deaths globally. A major clinical symptom associated with abstinence from both licit and illicit drugs is insomnia, which is a clinically verified, major risk factor for relapse. Roughly half of the 40 million smokers in the U.S. attempt to quit annually, with very low rates of success. One major hurdle is poor sleep quality during abstinence. Compounding the problem is that some pharmaceuticals to help reduce smoking can increase insomnia. Poor sleep is recognized as a major impediment to maintaining abstinence from several drugs of abuse, including nicotine. Blockers of orexin have recently been proposed as a promising therapy for smoking cessation. Insomnia has been reported in up to 40% of smokers, and 80% report regular sleep disturbances, which can be amplified during abstinence. A new orexin blocker, daridorexant, was FDA approved within the past two years for the treatment of insomnia, and while it has been tested in healthy individuals with insomnia, it has not been tested in smokers, who suffer from insomnia, particularly during the withdrawal phase when trying to quit. Daridorexant has an improved profile of beneficial effects for those with insomnia, the most notable advantage being its shorter duration of action that promotes daytime alertness, which is problematic for both active smokers and smokers during withdrawal. Poor sleep leads to daytime sleepiness, which often leads to smoking to maintain alertness.

A vizsgálat 2 csoportja

  • TreatmentMár használt kezelés, összehasonlításként

    Kezelés: Daridorexant 50 mg

  • No treatmentPlacebo, összehasonlításként

    Kezelés: Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking During Abstinence
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT07328594: ki vehet részt
A regiszteradat frissítve
2026. január 9.